来源：新浪证券-红岸工作室 2月27日，君实生物涨0.18%，成交额2.13亿元，换手率0.82%，总市值349.07亿元。 异动分析 猴痘概念+生物疫苗+创新药+AIGC概念 1、公司公众号：2023年10月27日，君实生物宣布，公司与北京大学、中国科学院微生物研究所（中科 院微生物所）、山西高等创新研究院、北京航空航天大学达成合作，共同开发猴痘重组蛋白疫苗。 2、2024年3月12日互动易：公司控股子公司君拓生物通过与科研院所和高校合作开发等形式持有疫苗相 关产品管线，如猴痘疫苗、寨卡疫苗等，目前均处于临床前开发阶段。 3、2024年年报，公司具备完整的从创新药物的发现和开发、 在全球范围内的临床研究、 大规模生产到 商业化的全产业链能力， 旨在成为立足中国、 布局全球的创新医药公司。 公司坚持质量为本、 求真务 实、 诚信合规、 追求卓越的企业价值观， 致力于通过源头创新以及合作开发等形式来研发 first-in-class （同类首创）或 best-in-class（同类最优） 的药物。 通过卓越的创新药物发现能力、 强大的生物技术研 发能力和大规模生产能力， 公司已成功开发出极具市场潜力的药品组合， ...

Market Overview - On February 25, the Shanghai Composite Index rose by 0.72% to 4147.23 points, the Shenzhen Component Index increased by 1.29% to 14475.86 points, and the ChiNext Index climbed by 1.41% to 3354.82 points. The total trading volume in the Shanghai and Shenzhen markets reached 2.46 trillion yuan, an increase of approximately 260.48 billion yuan compared to the previous trading day. A total of 3540 stocks rose, 1529 fell, and 121 remained unchanged, with thematic sectors showing strong performance [1]. Popular Stocks - The top ten popular stocks in A-shares include Baogang Group, Aerospace Development, Changchun High-tech, Yuntianhua, Hancable, Northern Rare Earth, Hebang Biotechnology, Jinzhengdai, Chuanjinnuo, and Lioo [1][2]. Baogang Group - Baogang Group's market attention is driven by its advantages in rare earth resources and the effectiveness of its strategic transformation. The price of rare earth concentrate has been raised for the sixth consecutive time, indicating an improvement in its bargaining power within the rare earth industry chain. The production of rare earth steel reached a historical high of 1.5 million tons, supported by its exclusive supply rights from the world's largest rare earth mine [3]. Aerospace Development - Aerospace Development's rise in popularity is attributed to dual advancements in governance optimization and strategic layout. The company has recently completed a standardized board of directors' restructuring and revised several management systems. Its subsidiary, Aerospace Tianmu, is advancing the "Tianmu No. 1" satellite project through capital increase and expansion, enhancing its strategic positioning in military informationization and commercial aerospace [3]. Changchun High-tech - Changchun High-tech is gaining attention due to significant breakthroughs in the innovative drug sector. The company has received clinical approval for the world's first ointment for treating pediatric micropenis and has strong sales for its IL-1β monoclonal antibody. Additionally, it secured a $1.365 billion overseas business development contract, marking a substantial business increment [4]. Yuntianhua - Yuntianhua's market interest stems from its resource advantages and external demand. The company possesses nearly 800 million tons of phosphate reserves with a self-sufficiency rate of 100%. The production of its 100,000-ton iron phosphate project has commenced, and the upcoming spring farming season is expected to boost phosphate fertilizer demand [4]. Hancable - Hancable's popularity is driven by technological advantages underpinned by policy support. The State Grid's investment plan of 4 trillion yuan is expected to stimulate demand for high-end cables, particularly in ultra-high voltage and flexible direct current sectors. The company has core technologies in ±535kV submarine cables and has optimized its governance structure to enhance competitiveness [5]. Northern Rare Earth - Northern Rare Earth's market focus is influenced by policy, supply-demand dynamics, and performance. As a leader in the rare earth industry, the company benefits from national protection policies and the tightening of supply controls, which have improved the supply-demand balance and driven up rare earth prices. The company's net profit is expected to increase by 116.67% to 1.346 billion yuan [5]. Hebang Biotechnology - Hebang Biotechnology's rise is linked to resource layout and positive business developments. The company has obtained exploration rights for over 1,000 square kilometers of gold mines in Australia and is advancing multi-metal mining projects in Xinjiang. Its methionine business is experiencing growth, and external factors such as rising commodity prices are enhancing profitability [6]. Jinzhengdai, Chuanjinnuo, and Lioo - Jinzhengdai is benefiting from increased attention in the fertilizer industry, with rising domestic urea prices and improved governance structure. Chuanjinnuo is seeing a significant profit increase of 144%-180% due to international phosphate prices exceeding $700 per ton. Lioo has capitalized on AI marketing and liquid cooling server trends, achieving a net profit increase of 469.1% [6].

2月25日，海普瑞涨0.74%，成交额3973.81万元，换手率0.26%，总市值179.45亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 来源：新浪证券-红岸工作室 资金分析 今日主力净流入-170.01万，占比0.04%，行业排名89/158，连续3日被主力资金减仓；所属行业主力净 ...

2月25日，长春高新盘中上涨2.04%，截至14:22，报90.22元/股，成交3.69亿元，换手率1.03%，总市值 368.04亿元。 资料显示，长春高新技术产业(集团)股份有限公司位于吉林省长春市高新海容广场B座27层(震宇街与东 蔚山路交汇),香港铜锣湾希慎道33号利园1期19楼1915室，成立日期1993年6月10日，上市日期1996年12 月18日，公司主营业务涉及生物制药及中成药的研发、生产和销售,辅以房地产开发、物业管理和服务 等业务。主营业务收入构成为：制药业92.83%，房地产6.81%，服务业0.36%。 长春高新所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：疫苗、肝炎治疗、 生物疫苗、东北振兴、阿尔茨海默等。 截至9月30日，长春高新股东户数10.41万，较上期减少4.63%；人均流通股3840股，较上期增加4.85%。 2025年1月-9月，长春高新实现营业收入98.07亿元，同比减少5.60%；归母净利润11.65亿元，同比减少 58.23%。 资金流向方面，主力资金净流入4389.73万元，特大单买入4206.91万元，占比11.42%，卖出1314.96万 ...

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. Product Pipeline and Achievements - Junshi Biosciences has a comprehensive capability in the entire industry chain from drug discovery and development to large-scale production and commercialization, aiming to become a global innovative pharmaceutical company based in China [3]. - The company’s core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review. It has also received approvals in multiple countries including the U.S., EU, and Australia [3]. - The company is advancing its proprietary drug tifcemalimab, which is the first anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III clinical trials and several Phase Ib/II studies in various tumor types [3]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was a loss of 596 million yuan, although this reflects a 35.72% improvement compared to the previous year [9]. Technological Advancements - The company has deployed an AI translation platform that has replaced over 80% of external translation services for scientific literature, clinical trials, and quality management, enhancing operational efficiency [4]. Market Position - As of February 10, 2023, Junshi Biosciences had a market capitalization of 36.673 billion yuan, with a trading volume of 3.32 billion yuan and a turnover rate of 1.21% [1].

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strategic focus on innovative vaccine development and expanding its product pipeline [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, holds vaccine-related product pipelines, including monkeypox and Zika vaccines, which are currently in preclinical development [2]. - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization [3]. Group 2: Product Pipeline and Achievements - Junshi's core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [3]. - The company has also developed Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III registration clinical trials [3]. - Multiple products are expected to initiate critical registration clinical trials by 2025, showcasing the company's commitment to innovation [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [9]. Group 4: Technological Advancements - Junshi has deployed an AI translation platform that has replaced over 80% of external translation services across various fields, enhancing operational efficiency [4]. - The company has introduced a digital employee, "i Xiao Jun," powered by AI, to support sales with medical information queries and provide IT system support [4].

来源：新浪证券-红岸工作室 2月9日，海普瑞涨0.82%，成交额5261.62万元，换手率0.34%，总市值180.62亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 该股筹码平均交易成本为11.66元，近期筹码减仓，但减仓程度减缓；目前股价靠近支撑位12.23，注意 支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建 ...

2月6日，新诺威盘中上涨2.05%，截至10:08，报35.38元/股，成交1.05亿元，换手率0.22%，总市值 496.94亿元。 截至1月30日，新诺威股东户数1.75万，较上期增加0.28%；人均流通股80349股，较上期减少0.27%。 2025年1月-9月，新诺威实现营业收入15.93亿元，同比增长7.71%；归母净利润-2404.89万元，同比减少 117.26%。 分红方面，新诺威A股上市后累计派现6.51亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年9月30日，新诺威十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股1778.22万股，相比上期减少321.69万股。中欧医疗健康混合A（003095）位居第三大流通股 东，持股1632.25万股，相比上期减少386.14万股。工银前沿医疗股票A（001717）位居第四大流通股 东，持股1400.01万股，相比上期增加200.01万股。汇添富创新医药混合A（006113）位居第五大流通股 东，持股1227.70万股，相比上期增加248.44万股。易方达创业板ETF（159915）位居第九大流通股东， 持股786.8 ...

来源：新浪证券-红岸工作室 2月4日，海普瑞涨1.33%，成交额5135.06万元，换手率0.34%，总市值179.01亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1918.43万，占总成交额的6.25%。 技术面：筹码平均交易成本为11.66元 该股筹码平均交易成本为11.66元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近压力位 12.37，谨防压力位处回调，若突破压力位则可能会 ...

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. - Junshi Biosciences has a complete industry chain capability from drug discovery and development to large-scale production and commercialization, aiming to become a globally positioned innovative pharmaceutical company [3]. Group 2: Product Pipeline and Innovations - The core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and an additional supplemental NDA under review, showcasing the company's strong market presence [3]. - The company’s self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III registration clinical studies and multiple Phase Ib/II studies in progress [3]. - Junshi Biosciences is exploring early-stage pipelines, with several products expected to initiate critical registration clinical trials by 2025 [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 4: Market Position and Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [9]. - The company is part of the pharmaceutical and biotechnology sector, focusing on biopharmaceuticals, including COVID-19 drugs, monkeypox concepts, viral prevention, and precision medicine [9].